Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept
Authors
Keywords
-
Journal
Scientific Reports
Volume 8, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-06-27
DOI
10.1038/s41598-018-28337-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial
- (2017) Francesco Tovoli et al. Future Oncology
- Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
- (2017) Masao Omata et al. Hepatology International
- Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation
- (2017) Franco Trevisani et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis
- (2017) Alessandro Granito et al. LANCET ONCOLOGY
- Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study
- (2017) Andrea Casadei Gardini et al. Scientific Reports
- The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation
- (2017) Matteo Ravaioli et al. Scientific Reports
- Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study
- (2016) Jorge A. Marrero et al. JOURNAL OF HEPATOLOGY
- Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance
- (2015) Irina Kareva et al. CANCER LETTERS
- Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure
- (2015) Alessandro Granito et al. DIGESTIVE AND LIVER DISEASE
- Reappraisal of shunt surgery for extrahepatic portal vein obstruction in adults: Report of a single-center case series
- (2015) Takashi Kokudo et al. HEPATOLOGY RESEARCH
- Sorafenib treatment in Child–Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors
- (2015) Sadahisa Ogasawara et al. INVESTIGATIONAL NEW DRUGS
- A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials
- (2014) Gemma Cramarossa et al. Biomarkers in Medicine
- Low-dose metronomic chemotherapy: A systematic literature analysis
- (2013) K. Lien et al. EUROPEAN JOURNAL OF CANCER
- Metronomic Capecitabine in Advanced Hepatocellular Carcinoma Patients: A Phase II Study
- (2013) G. Brandi et al. ONCOLOGIST
- Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
- (2012) T. Pressiani et al. ANNALS OF ONCOLOGY
- The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis
- (2012) Joanne Chiu et al. CANCER
- Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function
- (2012) Jon Zugazagoitia et al. Clinical & Translational Oncology
- Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score
- (2011) A. Hollebecque et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function
- (2011) Jeong Eun Kim et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy
- (2011) Massimo Iavarone et al. HEPATOLOGY
- Metronomic chemotherapy: new rationale for new directions
- (2010) Eddy Pasquier et al. Nature Reviews Clinical Oncology
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Sorafenib in Unresectable Hepatocellular Carcinoma from Mild to Advanced Stage Liver Cirrhosis
- (2009) M. Pinter et al. ONCOLOGIST
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started